Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines

The World Health Organization (WHO) and the Pan American Health Organization recommend that yellow fever and measles, mumps and rubella (MMR) vaccines be administered on the same day or at least 4 weeks apart to prevent interference between live vaccines. In 2011 a Brazilian study demonstrated lower seroconversion against yellow fever, rubella, and mumps when the two vaccines were administered on the same day compared with administering them separately. WHO urged that additional studies be conducted to examine this issue.

This Phase IV study aims to determine if seroconversion against measles, mumps, rubella, and yellow fever after administration of MMR and yellow fever vaccines on the same day is non-inferior to seroconversion after sequential administration 28 days apart in health 12-month old children.

Inclusion criteria

• Age 12 to 24 months at the time of enrollment
• Healthy child, determined by clinical history
• Availability to do study visits and blood sampling on days 28 + 7 and 56 + 14
• Informed consent signed by parents

Exclusion criteria

• Previous vaccination against yellow fever, measles, mumps, or rubella
• History of yellow fever, measles, mumps or rubella
• Contraindication for any of the study vaccines: yellow fever vaccine or triple viral vaccine, including:

• Allergy to eggs, gelatin, or neomycin
• Weakened immunological function, including HIV infection, primary immunodeficiencies, having received immunosuppressive doses of oral or injectable corticosteroids (or equivalent), having received immunomodulators or chemotherapeutic agents
• Thymus disease
• Serious illness/fever (mild illness without fever is not an exclusion criterion)
• Administration of immunoglobulins or other blood derivative within 6 months of enrollment in the study or during the study

a. Exception: children with a history of Kawasaki disease who received gammaglobulin cannot be enrolled if they received it in the previous 11 months.

• Administration of any other attenuated viral vaccine (i.e., for chickenpox) in the month prior to enrollment, or if the administration of any other attenuated viral vaccine is expected during the study (up to 3 months)
• Not being available for the entire study period (up to 3 months), or not able to make the scheduled visits or complete the study procedures
• Participating in another clinical drug trial of a drug, vaccine, or medical device
• Any condition that, in opinion of the study staff, represents a health risk to the participant or interferes with the evaluation of the response to the vaccine (i.e., children in percentile ≤ 3 in the height/weight tables will be considered undernourished and cannot be selected)